|
Chiron of the US is looking to sell its SBL vaccines division in Sweden, in order to help fund a £85m expansion plan that will safeguard 600 jobs at the recently-acquired Powderject plant on Merseyside. 13-Nov-2003 Powderject's new US parent Chiron is to relocate 12 senior managers from Uxbridge to the Powderject office in Oxford. 16-Jul-2003 Powderject is planning to invest £85m at its vaccine production plant in Liverpool over the next five years, with the creation of an unspecified number of jobs. 11-Jun-2003 Powderject, the vaccine maker, is to be acquired by Chiron of the US for more than £540m. 20-May-2003 Powderject, the vaccine maker, is facing the prospect of a £500m takeover bid from Chiron of the US. 28-Apr-2003 Powderject is to set up a direct sales force to sell its flu vaccine, with the creation of 25 jobs. 09-Oct-2002 Powderject Pharmaceuticals is in negotiations with an unnamed bidder to sell its needle-free injection technology, in order to focus on the production of vaccines. 12-Oct-2001 Powderject has announced plans to invest £13m at its Evans Vaccines plant in Speke, in order to increase production of flu vaccines. 02-Aug-2001 Powderject Pharmaceuticals has acquired SBL Vaccin, the Swedish vaccines company, for £35m, and is now looking to sell the rights to its needleless syringe. 04-Jul-2001 Powderject is to lease part of its recently-acquired vaccines plant in Speke to Aviron, which will enable the US company to set up a plant to manufacture flu vaccines. 12-Oct-2000 Powderject Pharmaceuticals has agreed to acquire the UK vaccines business of Celltech for £55m. 08-Sep-2000 Powderject is in negotiations to acquire Celltech's vaccines manufacturing business, which employs 600 people in Speke, for about £50m. 25-Aug-2000 Powderject has announced a £61m alliance with Ares-Serono of Switzerland to develop powdered fertility and immunology proteins for needle-free injection, and is raising £52m in a share placing. 12-Feb-1999 Powderject Pharmaceuticals has won a European patent for its DNA vaccine technology, which involves propelling DNA into the body using a helium jet. 02-Dec-1998 PowderJect Pharmaceuticals has announced the formation of partnerships with Zeneca and an unnamed Japanese company to collaborate on the development of its painless injection system. 09-Jun-1998 Powderject Pharmaceuticals has agreed to collaborate with Glaxo Wellcome on the development of DNA vaccines, and it could receive up to £180m in licence and milestone payments over the next 5-10 years. 05-Mar-1998 Powderject Pharmaceuticals has won FDA approval to begin clinical trials in the US on its technique for painlessly injecting anaesthetic. 11-Feb-1998 Powderject Pharmaceuticals is to link up with InSite Vision of the US to develop a technique for painlessly delivering drugs to the inside of the eyeball. 11-Dec-1997 Powderject has agreed a £9m deal with Boehringer Mannheim of Germany for the development and commercialisation of its alternative to needle injections. 10-Sep-1997 Powderject Pharmaceuticals is planning a flotation in June in order to raise about £30m to develop a patented device for painless injections. 30-Apr-1997
|